



1483 WO/US  
PATENT 2287

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of: Knight, et al.

Group Art Unit: 2287

Serial No.: 10/510,454

Filed: October 4, 2004

Confirmation No. 2287

Atty. File No.: 1483 WO/US

Title: Method for Obtaining a 2-18F-Fluor-2-Deoxy-D-Glucose (18F-FDG)-Solution

Examiner: Layla Bland

June 10, 2008

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Submission of Priority Document**

Applicant hereby submits a certified copy of European Application EP 02076638.2 as requested.

The Commissioner is hereby authorized to charge Deposit Account Number 13-1160 for a two-month late fee and any other fee deficiency in connection with this response.

Respectfully submitted,

Anthony R. Kinney, Reg. No. 44,834  
Covidien  
675 McDonnell Boulevard  
Hazelwood, Missouri 63042  
Telephone: (314) 654-8346  
Fax: (314) 654-3156



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr.    Patent application No.    Demande de brevet n°**

02076638.2

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**



Anmeldung-Nr.:  
Application no.: 02076638.2  
Demande no:

Anmeldetag:  
Date of filing: 24.04.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Mallinckrodt Inc.  
675 McDonnell Boulevard  
St. Louis, MO 63134  
ETATS-UNIS D'AMERIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Method for obtaining a 2- 18F fluor-2-deoxy-D-glucose (18F-FDG)-solution with  
improved physical/chemical stability and a (sterile) 2 18F fluor-2-deoxy-D-  
glucose (18F-FDG)-solution produced therewith

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K51/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

24. 04. 2002

1

94

METHOD FOR OBTAINING A 2- [ $^{18}\text{F}$ ] FLUOR-2-DEOXY-D-GLUCOSE ( $^{18}\text{F}$ -  
FDG) -SOLUTION WITH IMPROVED PHYSICAL/CHEMICAL STABILITY AND A  
(STERILE) 2- [ $^{18}\text{F}$ ] FLUOR-2-DEOXY-D-GLUCOSE ( $^{18}\text{F}$ -FDG) -SOLUTION  
PRODUCED THEREWITH

The present invention relates to a method for obtaining a 2- [ $^{18}\text{F}$ ] fluor-2-deoxy-D-glucose (also described herein as  $^{18}\text{F}$ -fluor-deoxy-glucose or  $^{18}\text{F}$ -FDG) -solution with improved physical/chemical characteristics, i.e.

5 radiochemical stability, and a (sterile)  $^{18}\text{F}$ -FDG-solution thus obtained.

In recent years, in the field of Nuclear Medicine, the compound  $^{18}\text{F}$ -FDG, aside from important uses in cardiology and neurology, has shown an ability to detect cancerous  
10 tissues undetectable by conventional means or to correct misdiagnosis of the disease. This is due to exploiting a fundamental change that occurs in cells when they become malignant; cancer cells lose their ability to efficiently convert glucose into energy. Consequently, they require much  
15 more glucose, up to 20 to 50 times more.

$^{18}\text{F}$ -FDG is usually prepared with the help of a fully automated synthesizer. Because the compound needs to be injected in patients, it is required that the solution containing the compound is sterilized prior to injection.  
20 However, the radiochemical purity of the compound decreases drastically during standard autoclaving steps and thus the compound fails to meet the specifications dictated by the European and United States Pharmacopeia. In addition, after synthesis,  $^{18}\text{F}$ -FDG rapidly loses in radiochemical purity due  
25 to both radiolysis and the half-life of the radioisotope, limiting the period in which the compound can be used.

It is the object of the present invention to provide a  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG) -solution which can be

autoclaved while still meeting the specification of more than 95% radiochemical purity eight hours after production. In addition, it is the object of the present invention to reduce, after synthesis, the effect of radiolysis of  $^{18}\text{F}$ -FDG in solution.

In the research leading to the present invention, it has been found that buffering the  $^{18}\text{F}$ -FDG-solution has a strong effect on the physical/chemical characteristics, i.e. the radiostability. It has been surprisingly found that buffers based on a weak acid improve the physical/chemical characteristics, i.e. the radiostability, of a  $^{18}\text{F}$ -FDG-solution to such extent that it becomes possible to autoclave this solution and maintain a radiochemical purity of at least 95%.

This is achieved according to the invention by a method comprising the following steps:

- a) provision of a  $^{18}\text{F}$ -fluor-deoxy-glucose ( $^{18}\text{F}$ -FDG)-solution, and
- b) addition of at least one buffer based on a weak acid to the  $^{18}\text{F}$ -FDG-solution.

The weak acid buffer should be physiologically acceptable and is preferably a citrate buffer, an acetate buffer, an ascorbate buffer or a combination of these buffers.

The improved physical/chemical characteristics of the  $^{18}\text{F}$ -FDG-solution are obtained when the pH of the citrate buffer is lower than 5.5, in particular between 2 and 5.5. For the acetate buffer, these characteristics are obtained at pH values between 3.0 and 5.5. The ascorbate buffer is used in a similar pH range as the acetate buffer between 3.0 and 5.5.

Autoclaving of the  $^{18}\text{F}$ -FDG-solution is performed at a temperature between 110°C and 150°C, preferably at a temperature between 130°C and 140°C and more preferably at a

temperature of 134°C. It was found that these temperatures are optimal considering stability and half-life of the  $^{18}\text{F}$  radio-isotope. The autoclaving process of the  $^{18}\text{F}$ -FDG-solution is performed during 1 to 30 minutes, preferably during 1 to 10 minutes and more preferably during 2 to 5 minutes. These ranges have been optimized considering the relatively short half-life of the  $^{18}\text{F}$  radio-isotope, which is 109.8 minutes.

The present invention will be further elucidated in the examples that follow and which are given for illustration purposes only and are not limiting the scope of the invention.

#### EXAMPLES

##### EXAMPLE 1

##### Autoclaving of a $^{18}\text{F}$ -FDG-solution at pH range 4.5 to 5.5

In this example, three test runs have been performed to study the radiochemical purity of a  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution buffered with a weak acid as compared to the non-buffered solution in saline.

Directly after production, the  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution is diluted with saline to a radioactive concentration of 3 mCi/ml at ART (Activity Reference Time) ( $t=0$ ). Two hours after production, vials with 0.5 ml of  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution were prepared, mixed with 0.1 ml of buffer (10 mM) and then autoclaved.

Table 1 illustrates the radiochemical purity of the differently buffered  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solutions after autoclaving during 5 minutes at 134°C. Measurements were carried out directly after autoclaving using a KAVO Sterimaster™.

**Table 1**Autoclaving of the  $^{18}\text{F}$ -FDG-solution at pH ranges 4.5 to 5.5

	Radiochemical purity of $^{18}\text{F}$ -FDG (%)		
	Test 1	Test 2	Test 3
Not autoclaved	98.85	96.41	95.9
Autoclaved			
Buffer/pH			
Ascorbate/4.5	94.5	95.0	94.7
Ascorbate/5.5	94.1	94.4	94.5
Citrate/4.5	97.3	96.5	96.3
Citrate/5.5	94.5	95.3	94.1
Acetate/4.5	96.5	94.6	94.5
Acetate/5.5	94.5	92.5	92.5
NaCl/6.2 (reference)	92.4	90.9	91.1

All the buffers tested gave a higher radiochemical purity than the non-buffered reference sample NaCl/pH 6.2. The buffer giving the best results is the citrate buffer with a pH of 4.5. As compared to the not autoclaved samples, only one out of three experiments showed a decrease in the radiochemical purity of 1% (test 1).

**Example 2**Autoclaving  $^{18}\text{F}$ -FDG-solution at low pH-ranges (pH 2-3)

In this example, two test runs have been performed to study the radiochemical purity of a  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution buffered with a weak acid to pH 2-3.

Directly after production, the  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution is diluted with saline to a

radioactive concentration of 3 mCi/ml at ART (12:00 h). Two hours after production, vials with 0.5 ml of  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution were prepared, mixed with 0.1 ml of buffer (100 mM) and then autoclaved

5 Table 2 illustrates the radiochemical purity of the differently buffered  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solutions after autoclaving during 5 minutes at 134°C.

**Table 2**

10 Autoclaving  $^{18}\text{F}$ -FDG-solution at low pH-ranges (pH 2-3)

Buffer	pH	Radiochemical purity of $^{18}\text{F}$ -FDG (%)	
		test 1	test 2
Ascorbate	3.0	97.8	98.0
15 Citrate	2.0	98.7	98.5
Acetate	3.0	97.4	97.3
NaCl (reference)	6.2	90.9	91.1

20 All three buffers tested yielded a higher radiochemical purity than the non-buffered reference sample NaCl/pH 6.2. Compared to the reference sample (decrease in radiochemical purity 9%) only a 2-3% decrease in radiochemical purity was observed for the samples buffered  
 25 with a weak acid. For all buffers (ascorbate, citrate and acetate), no significant decrease in the radiochemical purity was measured as compared to the non-autoclaved samples (Table 1).

### 30 **EXAMPLE 3**

#### Radiolysis of $^{18}\text{F}$ -FDG



The radiolysis of  $^{18}\text{F}$ -FDG was measured during a period of approximately 8.5 hours. The radioactive concentration was 3 mCi/ml at ART ( $t=0$ ).

Two buffers were tested and compared to the reference sample in 0.9% NaCl/pH 6.9. The first buffer was a citrate buffer pH 4.5 and the second buffer an ascorbate buffer pH 4.5. Five determinations of the radiochemical purity of the samples were conducted during the interval. The results are illustrated in table 3.

**Table 3**

Radiolysis of a  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution.

buffer/pH	time of determination (min)	percentage $^{18}\text{F}$ -FDG
citrate buffer, pH 4.5	0	98.98
	46	98.03
	203	96.18
	317	95.31
	495	94.73
ascorbate buffer, pH 4.5	0	98.98
	64	97.96
	213	97.55
	327	97.37
	505	97.28
0.9% NaCl, pH 6.90	0	98.98
	94	96.51
	230	94.74
	340	94.13
	516	93.59

Radiolysis in both buffers tested was decreased as compared to the 0.9% NaCl sample. The largest decrease in radiolysis was observed when using the ascorbate buffer. Only a 2% decrease in activity was observed after 8.5 hours. This decrease was 4% and 6% for the citrate buffer and the 0.9% NaCl, respectively. In conclusion,  $^{18}\text{F}$ -FDG is more stable after addition of an ascorbate or citrate buffer than without the addition of these buffers.

#### 10 **EXAMPLE 4**

##### Autoclaving and radiolysis of $^{18}\text{F}$ -fluor-deoxy-glucose (FDG) - solutions

The radiolysis of  $^{18}\text{F}$ -FDG was measured during a period of approximately 7.5 hours after autoclaving the sample. Two buffers were tested and compared to the reference sample in 0.9% NaCl/pH 6.9. The first was a citrate buffer pH 4.5 and the second an ascorbate buffer pH 4.5. Three determinations of the radiochemical purity of the samples were conducted during the interval. The results are illustrated in table 4.

**Table 4**

Autoclaving and radiolysis of a  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG) - solution

	Radiochemical purity of $^{18}\text{F}$ -FDG (%)			
	autoclaved			not autoclaved
Time of determination (min)	citrate	ascorbate	NaCl	NaCl
0	97.37	95.56	89.56	97.49
240	95.55	94.65	87.49	95.30
453	95.35	94.50	86.77	94.61

After addition of a weak acid buffer  $^{18}\text{F}$ -FDG is stable under autoclavation conditions. Without addition of this buffer, the radiochemical purity of the sample drops dramatically to less than 90%. A citrate buffer yields better stability of the  $^{18}\text{F}$ -FDG-solution as compared to ascorbate. In addition, radiolysis, after autoclaving, in both buffers tested was decreased as compared to the NaCl sample. The largest decrease in radiolysis was observed when the ascorbate buffer was used. Only a 1% decrease in activity was observed after 7.5 hours. This decrease was 2% and 3% for the citrate buffer and the NaCl sample, respectively. In conclusion, the  $^{18}\text{F}$ -FDG-solution is more stable after addition of an ascorbate or citrate buffer than without the presence of these buffers during autoclavation. After autoclaving, in both buffers the radiolysis of the  $^{18}\text{F}$ -FDG-solution was reduced.

## CLAIMS

94

1. Method for improving one or more physical/chemical characteristics of a  $^{18}\text{F}$ -fluor-deoxy-glucose ( $^{18}\text{F}$ -FDG)-solution, which method comprises the steps of:

a) provision of a  $^{18}\text{F}$ -fluor-deoxy-glucose ( $^{18}\text{F}$ -FDG)-  
5 solution, and

b) addition of at least one buffer based on a weak acid to the  $^{18}\text{F}$ -fluor-deoxy-glucose ( $^{18}\text{F}$ -FDG)-solution.

2. Method according to claim 1, wherein the improved physical/chemical characteristic is the ability of  
10 the  $^{18}\text{F}$ -FDG-solution to be autoclaved, thus rendering the solution suitable for medical application.

3. Method according to claim 1 or claim 2, wherein the improved physical/chemical characteristic is reduced radiolysis in the  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution.

15 4. Method according to claims 1-3, wherein the buffer based on a weak acid, is selected from the group consisting of citrate, acetate, ascorbate and combinations thereof.

20 5. Method according to claims 1-4, wherein the pH of the citrate buffer is lower than 5.5, preferably between pH 2 and 5.5.

6. Method according to claims 1-4, wherein the pH of the acetate buffer is between 3.0 and 5.5.

25 7. Method according to claims 1-4, wherein the pH of the ascorbate buffer is between 3.0 and 5.5.

8. Method of preparing a sterile  $^{18}\text{F}$ -fluor-deoxy-glucose ( $^{18}\text{F}$ -FDG)-solution by autoclaving a  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution obtainable by any of the claims 1-7.

30 9. Method according to claim 8, wherein the  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution is autoclaved at a temperature between  $110^{\circ}\text{C}$  and  $145^{\circ}\text{C}$ , preferably at a

temperature between 130°C en 140°C and more preferably at a temperature of 134°C.

10. Method according to claim 8 or 9, wherein the autoclaving process is performed during 1 to 30 minutes, preferably during 1 to 10 minutes and more preferably during 2 to 5 minutes.

11.  $^{18}\text{F}$ -fluor-deoxy-glucose (FDG)-solution with improved physical/chemical characteristics obtainable by the method according to any one of the claims 1-7.

10 12. Sterile  $^{18}\text{F}$ lucose (FDG)-solution obtainable by any of one the claims 8-10.